Production of Recombinant S1 Protein of Porcine Epidemic Diarrhea Virus in Recombinant CHO Cells for Application in Indirect ELISA
Journal of Microbiology and Biotechnology · 2025
DOI: 10.4014/jmb.2506.06050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Microbiology and Biotechnology, 2025. Verfasst von Eun-Ji Lee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Biotherapeutics Translational Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Republic of Korea. Hauptthemen laut MEDLINE: Porcine epidemic diarrhea virus, Spike Glycoprotein, Coronavirus, Coronavirus Infections. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Research Foundation of Korea, Korea Research Institute of Bioscience and Biotechnology, Ministry of Trade, Industry and Energy.
Abstract (Originalsprache)
The N-terminal S1 subunit of the spike protein (S1 protein) of porcine epidemic diarrhea virus (PEDV) is recognized as a potential diagnostic antigen for detecting anti-PEDV immunoglobulin A (IgA) levels in colostrum, a key indicator for assessing passive immunity against PEDV infection. Given the advantages of producing Fc-fusion proteins in mammalian cells, it is important to investigate how the addition of the Fc region affects the diagnostic performance of the PEDV-S1 protein. In this study, we successfully produced full-length PEDV-S1 protein fused with an Fc region (PEDV-S1-Fc protein) via transient gene expression in recombinant Chinese hamster ovary (rCHO) cells adapted to serum-free suspension culture. The resulting expression showed significantly higher volumetric productivity than previously reported. The aglycosylated form of PEDV-S1-Fc protein was also generated using PNGase F treatment of the purified protein, as well as tunicamycin treatment to inhibit glycosylation during cell culture. Notably, neither the addition of the Fc region nor the removal of N-glycans markedly affected the diagnostic function, as demonstrated by indirect ELISA using PEDV-positive and PEDV-negative colostrum samples. Moreover, the diagnostic performance of the PEDV-S1-Fc protein was further validated using total IgA purified from PEDV-positive colostrum. In summary, the full-length Fc-fused PEDV-S1 protein produced in rCHO cell culture exhibited high productivity and purity, making it a promising antigenic candidate for indirect ELISA-based detection of anti-PEDV IgA in colostrum.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biotherapeutics Translational Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Republic of Korea.
- Department of Bioprocess Engineering, KRIBB School of Biotechnology, University of Science and Technology (UST), Daejeon, Republic of Korea.
- Choong Ang Vaccine Laboratory Co., Ltd. (CAVAC), Daejeon, Republic of Korea.
Förderung
- National Research Foundation of Korea
- Korea Research Institute of Bioscience and Biotechnology
- Ministry of Trade, Industry and Energy
Zitieren
APA
Lee, E. J., Kim, S., Kim, T. H., Heo, N. Y., Kim, H. S., Ryu, S. H., Koo, S. J., Won, H., & Kim, Y. G. (2025). Production of Recombinant S1 Protein of Porcine Epidemic Diarrhea Virus in Recombinant CHO Cells for Application in Indirect ELISA. Journal of Microbiology and Biotechnology. https://doi.org/10.4014/jmb.2506.06050
Vancouver
Lee EJ, Kim S, Kim TH, Heo NY, Kim HS, Ryu SH, et al. Production of Recombinant S1 Protein of Porcine Epidemic Diarrhea Virus in Recombinant CHO Cells for Application in Indirect ELISA. Journal of Microbiology and Biotechnology. 2025. doi:10.4014/jmb.2506.06050
BibTeX
@article{Lee2025,
author = {Lee, Eun-Ji and Kim, Sungkyun and Kim, Tae-Ho and Heo, Na-Yeong and Kim, Hyun-Seung and Ryu, So Hui and Koo, Seung Jin and Won, Hokeun and Kim, Yeon-Gu},
title = {Production of Recombinant S1 Protein of Porcine Epidemic Diarrhea Virus in Recombinant CHO Cells for Application in Indirect ELISA},
journal = {Journal of Microbiology and Biotechnology},
year = {2025},
doi = {10.4014/jmb.2506.06050}
}
EUVIMED